Skip to main content
Defiance International

Published study records

Study records for ARA-290

Study records describe published research and its limitations. They do not establish efficacy, safety, or suitability for any use.

Study record counts

64 study records.

0 evidence-verified · 45 citation-verified · 19 identifier-confirmed · 0 citation-only

Listed by tier, then records with a public summary first, then publication year, newest first, undated last.

Verified records by research setting

  • In vitro: 6
  • In vivo/preclinical: 31
  • Review/meta-analysis: 3
  • Other: 0
Filter study recordsReset filters

Filtered results

Study type: Human research · Verification: Citation verified

  • 2016

Targeting the innate repair receptor to treat neuropathy.

Pain reports · 2016

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation verified. The PMID shown was confirmed at PubMed on 2026-08-20, and its study type matched the catalog’s source record. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vitro · Verification: Citation verified

  • 2015

Modulation of cellular stress response via the erythropoietin/CD131 heteroreceptor complex in mouse mesenchymal-derived cells.

Journal of molecular medicine (Berlin, Germany) · 2015

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation verified. The PMID shown was confirmed at PubMed on 2026-08-16, and its study type matched the catalog’s source record. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: Narrative review · Verification: Citation verified

  • 2015

Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin.

Pharmacology & therapeutics · 2015

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation verified. The PMID shown was confirmed at PubMed on 2026-08-16, and its study type matched the catalog’s source record. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: Human research · Verification: Citation verified

  • 2015

Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2015

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation verified. The PMID shown was confirmed at PubMed on 2026-08-16, and its study type matched the catalog’s source record. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vivo/preclinical · Verification: Citation verified

  • 2014

A non-erythropoietic peptide derivative of erythropoietin decreases susceptibility to diet-induced insulin resistance in mice.

British journal of pharmacology · 2014

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation verified. The PMID shown was confirmed at PubMed on 2026-08-16, and its study type matched the catalog’s source record. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vivo/preclinical · Verification: Citation verified

  • 2014

Therapeutic effects of nonerythropoietic erythropoietin analog ARA290 in experimental autoimmune encephalomyelitis rat.

Journal of neuroimmunology · 2014

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation verified. The PMID shown was confirmed at PubMed on 2026-08-16, and its study type matched the catalog’s source record. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: Narrative review · Verification: Citation verified

  • 2014

ARA 290 for treatment of small fiber neuropathy in sarcoidosis.

Expert opinion on investigational drugs · 2014

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation verified. The PMID shown was confirmed at PubMed on 2026-08-16, and its study type matched the catalog’s source record. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vivo/preclinical · Verification: Citation verified

  • 2014

ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response.

Molecular pain · 2014

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation verified. The PMID shown was confirmed at PubMed on 2026-08-16, and its study type matched the catalog’s source record. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vivo/preclinical · Verification: Citation verified

  • 2013

ARA290 in a rat model of inflammatory pain.

Methods in molecular biology (Clifton, N.J.) · 2013

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation verified. The PMID shown was confirmed at PubMed on 2026-08-16, and its study type matched the catalog’s source record. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vivo/preclinical · Verification: Citation verified

  • 2013

Ketamine does not produce relief of neuropathic pain in mice lacking the β-common receptor (CD131).

PloS one · 2013

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation verified. The PMID shown was confirmed at PubMed on 2026-08-20, and its study type matched the catalog’s source record. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vivo/preclinical · Verification: Citation verified

  • 2013

The erythropoietin-derived peptide ARA290 reverses mechanical allodynia in the neuritis model.

Neuroscience · 2013

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation verified. The PMID shown was confirmed at PubMed on 2026-08-16, and its study type matched the catalog’s source record. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vivo/preclinical · Verification: Citation verified

  • 2013

Renoprotective capacities of non-erythropoietic EPO derivative, ARA290, following renal ischemia/reperfusion injury.

Journal of translational medicine · 2013

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation verified. The PMID shown was confirmed at PubMed on 2026-08-20, and its study type matched the catalog’s source record. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.